UroGen Pharma Ltd. (0XOD.L)

13.50 -0.64 (-4.53%) As of 05:14PM BST. Market open.

UroGen Pharma Ltd.

400 Alexander Park Drive
4th Floor
Princeton, NJ 08540
United States
(646) 768-9780
https://www.urogen.com

Sector(s): 
Industry: 
Full-time employees: 198

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Elizabeth A. Barrett	President, CEO & Director	1.12M	N/A	1962
Mr. Dong Kim	Chief Financial Officer	546.68k	N/A	1977
Mr. Jason Drew Smith	General Counsel, Chief Compliance Officer & Corporate Secretary	717.58k	N/A	1972
Vincent I. Perrone	Senior Director of Investor Relations	N/A	N/A	N/A
Mr. Bryon Wornson	Executive Vice President of Talent, Advocacy & Communications	N/A	N/A	N/A
Dr. Sari Prutchi-Sagiv Ph.D.	Marketing Director	N/A	N/A	N/A
Dr. Marina Konorty	Executive Vice President of Research & Development and Technical Operations	N/A	N/A	N/A
Dr. Mark P. Schoenberg M.D.	Chief Medical Officer	579.5k	N/A	1958
Mr. Jeffrey Bova M.B.A.	Chief Commercial Officer	N/A	N/A	N/A
Mr. James Ottinger R.ph.	Executive Vice President of Regulatory Affairs & Quality	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Corporate governance

UroGen Pharma Ltd.’s ISS governance QualityScore as of 1 April 2024 is 3. The pillar scores are Audit: 6; Board: 2; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.